MVP
$44MCF+
Medical Developments International
Pain management
Manufacturer of Penthrox (inhaled methoxyflurane) for acute pain — approved in 20+ countries
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$18.6M
Mar 2026 4C
Runway
CF+Cash Flow Positive
Based on Mar 2026 4C
Market Cap
$44M
Burn Rate
—
Mar 2026 4C
Shares Outstanding
113M
Pipeline Assets
3
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveQuarterly 4C23 Apr 2026
Appendix 4C and Quarterly Activity Report 31 March 2026
Cash$18.7M·Burn$2.5M/q·OCF$2.5M
3M Price
MVP.ASX$0.390-3.7% 3M
Low $0.370High $0.475
Pipeline Assets (3)
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Substantial Holders (5%+ threshold)
3 noticesarrow_drop_upJencay Capital Pty Limited
6.38%2026-06-02
arrow_drop_downRegal Partners Funds Management Pty Limited and its associates
Catalysts (1)
SpeculativeremoveMed1 June 2029
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| PHASE3 data readout — Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute open_in_new Primary completion expected for NCT07445737. Indication: {"STEMI - ST Elevation Myocardial Infarction"} | data readout | Speculative | removeMed |
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High93/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filed 2 of 2 4Cs on time· statutory deadline
What drove these scores · rolling 2yr
arrow_drop_up
Cash-flow positive — 2/2 quarters with positive operating cash flow
arrow_drop_up
Cash position improving — Cash balance growing
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
Ph3Not Yet Recruiting
MethoxyfluraneMorphine
Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction
STEMI - ST Elevation Myocardial Infarction
RandomizedOpen Label18 Years+
Primary endpoint Demonstrate that methoxyflurane self-administered by the patient is at least as efficient in achieving pain relief that morphine
ENROL700
no manual snapshots — enter via record_enrollment.py
Announcements(11)
payments
Quarterly 4CPSauto_awesome
Appendix 4C and Quarterly Activity Report 31 March 202623 Apr 2026
expand_more324KB